Diagnose und Therapie der
heparininduzierten Thrombozytopenie

A Link; J Pöss; M Böhm

doi:10.1055/s-0031-1275831

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2011; 136(18): 953-962
DOI: 10.1055/s-0031-1275831

CME | Review article

Kardiologie, Angiologie
© Georg Thieme Verlag KG Stuttgart · New York

Diagnose und Therapie der heparininduzierten Thrombozytopenie

Diagnosis and treatment of heparin-induced thrombocytopeniaA. Link¹ , J. Pöss¹ , M. Böhm¹

¹Klinik für Innere Medizin III, Universität des Saarlandes, Homburg/Saar

Abstract

Schlüsselwörter

Heparin - Thrombozytopenie - Thromboembolie - Antikoagulation - Thrombininhibitoren

Keywords

heparin - thrombozytopenia - thromboembolism - anticoagulation - thrombin inhibitors

Full Text

References

Literatur

1 Arepally G M, Ortel T L. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006; 355 809-817
2 Begelman S M, Baghdasarian S B, Singh I M. et al . Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intensive Care Med. 2008; 23 313-320
3 Beiderlinden M, Treschan T A, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007; 41 749-754
4 Cochran K, DeMartini T J, Lewis B E. et al . Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J Invasive Cardiol. 2003; 15 617-621
5 Efird L E, Kockler D R. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother. 2006; 40 1383-1387
6 Eichler P, Friesen H J, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000; 96 2373-2378
7 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001; 85 950-957
8 Fischer K G. Hirudin in renal insufficiency. Semin Thromb Hemost. 2002; 28 467-482
9 Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009; 7 Suppl 1 9-12
10 Greinacher A, Althaus K, Krauel K, Selleng S. Heparin-induced thrombocytopenia. Hamostaseologie. 2010; 30 17-18
11 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000; 96 846-851
12 Greinacher A, Farner B, Kroll H. et al . Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005; 94 132-135
13 Greinacher A, Juhl D, Strobel U. et al . Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007; 5 1666-1673
14 Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest. 2005; 127 1S-8S
15 Hursting M J, Verme-Gibboney C N. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol. 2008; 52 561-566
16 Keegan S P, Ernst N E, Mueller E W. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009; 37 2139; author reply 2139-2140
17 Kern H, Ziemer S, Kox W J. Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med. 1999; 25 1311-1314
18 Kiser T H, Burch J C, Klem P M, Hassell K L. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008; 28 1115-1124
19 Kiser T H, Fish D N. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006; 26 452-460
20 Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg. 2006; 132 699-700
21 Krauel K, Pötschke C, Weber C. et al . Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011; 117 (4) 1370-1378
22 Lewis B E, Matthai Jr W H, Cohen M. et al . Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002; 57 177-184
23 Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost. 2001; 7 300-304
24 Lindhoff-Last E, Piechottka G P, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res. 2000; 100 55-60
25 Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009; 37 105-110
26 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4 759-765
27 Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood. 2004; 104 3072-3077
28 Lubenow N, Eichler P, Lietz T. et al . Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospecive study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005; 3 2428-36
29 Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs. 2000; 14 109-125
30 Lubenow N, Hinz P, Thomaschewski S. et al . The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010; 115 1797-1803
31 Magnani H N. A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis. Thromb Res. 2010; 125 e171-e176
32 Magnani H N, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost. 2006; 95 967-981
33 Mahaffey K W, Lewis B E, Wildermann N M. et al . The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003; 15 611-616
34 Martel N, Lee J, Wells P S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106 2710-2715
35 Murray P T, Reddy B V, Grossman E J. et al . A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004; 66 2446-2453
36 Oliveira G B, Crespo E M, Becker R C. et al . Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008; 168 94-102
37 Polkinghorne K R, McMahon L P, Becker G J. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis. 2002; 40 990-995
38 Rauova L, Zhai L, Kowalska M A. et al . Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006; 107 2346-2353
39 Reddy B V, Grossman E J, Trevino S A, Hursting M J, Murray P T. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005; 39 1601-1605
40 Selleng S, Malowsky B, Itterman T. et al . Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J. 2010; 160 362-369
41 Vargas Hein O, Kox W J, Spies C. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol. 2004; 144 308-316
42 Vargas Hein O, von Heymann C, Lipps M. et al . Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med. 2001; 27 673-679
43 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res. 2003; 110 73-82
44 Warkentin T E, Greinacher A, Koster A, Lincoff A M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 340S-380S
45 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101 502-507
46 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001; 135 502-506
47 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001; 344 1286-1292
48 Warkentin T E, Maurer B T, Aster R H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007; 356 2653-2655
49 Selleng K, Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia in intensiv care patients. Crit Care Med. 2007; 35 1165-1176

PD Dr. med. Andreas Link

Klinik für Innere Medizin III
Universität des Saarlandes

Kirrberger Straße

66421 Homburg / Saar

Phone: 06841/1623372 oder -1623341

Fax: 06841/1623369

Email: andreas.link@uks.eu